CD274 and cancer: Moreover, meta-analysis studies have determined the efficacy of PD-1/PD-L1 inhibitors in clinical trials, highlighting their potential as effective immunotherapeutic agents across various cancer types, drug combinations, stages of treatment, and therapeutic schedules (31).